Austin Neuromuscular Center

This is a small, early-stage pilot study testing whether a combination of two drugs, pozelimab and cemdisiran, can help control the progression of sporadic inclusion body myositis (sIBM), a rare muscle-wasting disease. Ten participants will receive injections every four weeks for…